Zacks Reiterates Outperform Rating, $9.50 PT on POZEN on PA-325/40 Product Data Presentations
March 06, 2013 at 14:12 PM EST
In a report published Wednesday, Zacks reiterated its Outperform rating and $9.50 price target on POZEN (NASDAQ: POZN ). Zacks noted, “The phase 3 clinical data on Pozen s PA-325/40 product has been presented now at three high-profile medical meetings, ACG in October 2012, AHA in November 2012, and AHA-Stroke
